[ivory-search id="184" title="Recordati AJAX Search Form"]

Who We Are

Of the 7,000 known rare diseases, less than 10% have an available treatment option. Our mission is to reduce the impact of rare and devastating diseases by providing urgently needed medicines.

At Recordati Rare Diseases we have decades of passion and experience in bringing treatments to those who suffer from rare diseases.

We work alongside global networks of patients, patient groups, experts, healthcare professionals, scientists, policy makers and regulators to educate communities and improve access.

Advocacy Groups

We have unparalleled experience in the development of clinical trials for orphan drugs and in specialist regulatory requirements.

Clinical Trials
Our infrastructure has been developed to uniquely produce, package and distribute specialist products worldwide.
Global R&D

Partnering

Recordati continuously develops specialty products originating either internally or by being acquired through agreements with other pharmaceutical companies and research institutes.


We specialize in inborn errors of metabolism, rare endocrine disorders, lysosomal storage disorders, and rare hematologic/oncologic conditions. Recordati Rare Diseases is dedicated to supporting all healthcare professionals, including geneticists, endocrinologists, nephrologists, ophthalmologists, and hematologists.


We are proven industry partners, utilizing our extensive network and knowledge within the rare disease community to maximize benefit to patients.


If you have a marketed rare disease product or a therapy in clinical development that targets a rare disease and you are interested in exploring North American partnership opportunities with Recordati Rare Diseases, please contact us at .

 

If you are interested in partnership opportunities outside North America, please contact .

MILESTONES

1926

Giovanni Recordati founds the Laboratorio Farmacologico Reggiano in Correggio (RE, Italy)

1953

Transfer of headquarters to Milan

1961

Recordati – Syntex (now part of Roche) licence agreement. Located in Silicon Valley, Syntex was a pioneering company in the study and synthesis of steroid hormones

1963

Inauguration of the pharmaceutical chemical plant in Campoverde di Aprilia

1984

Listing on the Italian Stock Exchange

1995

Beginning the process of internationalisation – Establishment of a subsidiary in Spain, now called Casen Recordati

1999

Acquisition of Doms Adrian (France)

2000

Acquisition of Bouchara (France)

2001

Establishment of Bouchara Recordati in France

2005
  • Acquisition of Merckle Recordati in Germany, now Recordati Pharma
  • Establishment of Recordati Pharmaceuticals in the United Kingdom
  • Establishment of Recordati Hellas in Greece
  • Establishment of the new pharmaceutical chemical plant in Cork, Ireland
2006

Acquisition of the Grupo Jaba companies in Portugal, today Jaba Recordati

2007

Entry to the rare diseases sector with the acquisition of Orphan Europe, now Recordati Rare Diseases

2008
  • Acquisition of FIC and FIC Médical, dedicated to the registration and promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries
  • Acquisition of Yeni Ilaç in Turkey, today Recordati Ilaç
2009

Acquisition of Herbacos-Bofarma in the Czech Republic and Slovakia, today Herbacos Recordati

2010

Acquisition of ArtMed International in Romania, now Recordati Romania

2011

Acquisition of Dr. F. Frik Ilaç in Turkey, now Recordati Ilaç

2012
  • Entry into the US market rare diseases sector
  • Acquisition of product portfolio for the treatment of a number of rare diseases in the US
  • Acquisition of Farma-Projekt in Poland, now Recordati Polska
2013
  • Acquisition of Opalia Pharma and its cGMP certified production facilities in Tunisia, now Opalia Recordati
  • Acquisition of Laboratorios Casen Fleet and its cGMP certified production facilities in Spain, now Casen Recordati
2015

Establishment of new subsidiaries in Brazil, Mexico and Colombia 

2016
  • SPC and OTC portfolio strengthened
  • Acquisition of Italchimici in Italy
  • Acquisition of Pro Farma AG, now Recordati AG, in Switzerland and Austria
2017
  • Acquisition of Natural Point in Italy
  • Acquisition of Tonipharm in France 
  • Establishment of new subsidiaries in Japan and Australia
2019
  • Expansion of the rare diseases product portfolio: entry into the endocrinology sector
  • Establishment of Recordati Bulgaria
2021-present
  • Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on rare diseases and niche oncology
Advocacy Partners

Recordati Rare Diseases is dedicated to supporting patients throughout their journeys. Below you can find links to our advocacy partners who support this mission:

logo-acromegaly_0
Acromegaly Community
The mission of the Acromegaly Community is to provide an emotional and communal support network for people touched by Acromegaly. We offer a central location for medical information on issues including: surgery, medication, radiation, and post diagnosis support. Most importantly, we work to provide a network of emotional support for our Acromegaly patients, their friends and their family.
card-APF
American Porphyria Foundation
The American Porphyria Foundation has supported the Porphyria community since 1983. Our mission is to improve the health and well-being of all individuals and families impacted by Porphyria. We have maintained a relentless focus on education, advocacy, support services and research for the prevention, treatment and cure of the Porphyrias.
card-CDCN
The Castleman Disease Collaborative Network
The Castleman Disease Collaborative Network (CDCN) is a global, nonprofit organization dedicated to accelerating research and treatment for this rare and often deadly disease, supporting patients on their journeys, and revolutionizing biomedical research to cure countless other diseases.
card-CSRF
Cushings Support and Research Foundation
The Cushing’s Support & Research Foundation aims to provide support and information about Cushing’s Disease and Syndrome to patients, providers, and others within our community. We promote awareness and education via outreach and research collaborations with investigators who realize that the self-reported patient experience is a crucial element to improving understanding and treatment outcomes.
card-CRF
Cystinosis Research Foundation
The Cystinosis Research Foundation is committed to funding research that will lead to better treatments and a cure for cystinosis and to educating the public and medical community to ensure early diagnosis and proper treatment.
card-cystinosis-research-network
Cystinosis Research Network
The Cystinosis Research Network is dedicated to supporting and advocating research, providing family assistance, and educating the public and medical community about cystinosis.
card-EVAN
Evan's Victory Against Neuroblastoma Foundation
Evan’s Victory Against Neuroblastoma Foundation serves the childhood cancer community through research, patient & survivor wellness, and advocacy & education programs. Our inspiration is Evan Lindberg, who passed away from neuroblastoma at the age of 7 following a 4-year battle that defined courage. Established in 2011, The EVAN Foundation brings joy to childhood cancer patients today and drives progress for a better tomorrow.
logo-HCU-Network
HCU Network America
The mission of HCU Network America is to help patients with homocystinuria and related disorders manage their disease and to find a cure.
card-nord
National Organization for Rare Disorders (NORD)
NORD is leading the fight to improve the lives of rare disease patients and families. We do this by supporting patients and organizations, accelerating research, providing education, disseminating information, and driving public policy.
card-nucdf
National Urea Cycle Disorders Foundation (NUCDF)
The National Urea Cycle Disorders Foundation (NUCDF) is dedicated to saving children and adults from the catastrophic effects of urea cycle disorders (UCDs). NUCDF is the leader in the fight to conquer UCDs, raising awareness to improve early diagnosis, catalyzing research, and is a vital resource of information and education for families and medical professionals. NUCDF is a lifeline for affected families seeking guidance and support, providing mentors for newly diagnosed families and networking UCD families together for support.
card-PNA
Pituitary Network Assoicataion
The PNA is an international non-profit organization for patients with pituitary tumors and disorders, their families, loved ones, and the physicians and health care providers who treat them. PNA was founded in 1992 by a group of acromegalic patients in order to communicate and share their experiences and concerns. PNA has rapidly grown to become the world’s largest and fastest growing patient advocacy organization devoted to the treatment and cure of pituitary disorders.
card-pituitary
Pituitary World News
Pituitary World News is an information network of expert scientist, clinicians and individuals impacted by pituitary diseases. The mission of PWN is to bring up-to-date information pertaining to health-related matters of importance to those with pituitary tumors.
card-conley-cushings
The Conley Cushing’s Disease Fund
The Conley Cushing’s Disease Fund was established on July 17, 2014 and is a project of The Foundation for Enhancing Communities, fiscal sponsor. The funds raised will be used in part to create awareness and advocacy for patients and their loved ones who are suffering from this disease as well as support institutions and organizations focused on research and treatment surrounding Cushing’s Disease.
Tailored, patient-centric development and clinical trial methodology

Rare diseases and orphan drugs undergo the same review processes as other pharmaceuticals and must meet the same high standards of quality, safety and efficacy. The small numbers of patients affected by a rare disease and the variability of any inherited trait (the so-called high phenotypic heterogeneity) means that randomized clinical trials are not always feasible for a rare diseases or orphan drug. Also, the use of placebo-controlled trials may be unethical and for comparisons standardised treatments are often not available.

Pharmaceutical Manfucaturing Plants

Recordati’s production sites are equipped with state-of-the-art installations and their research laboratories are fitted with the latest equipment. All plants operate in full compliance with environmental protection regulations and in compliance with the current Good Manufacturing Practices (cGMP). 

 

See all here: https://recordati.com/industrial-operations/

Specialist packing and distribution centre
We have a packaging and distribution site in Paris exclusively dedicated to products for the treatment of rare diseases. It occupies a surface area of 1,600 sq. m. and is entirely dedicated to the secondary packaging, storage and shipping of rare disease products. The site delivers, upon short notice, more than 27,000 orders annually to more than 60 countries worldwide thanks to its highly qualified staff and a modern Good Distribution Practices (GDP) certified logistics platform.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site
Recordati for the planet
A clean environment is essential for people’s well-being: the health of the planet and the health of people is tightly interconnected. Environmental elements, such as air, water, land and climate, all have an impact on the well-being of humans. Placing a focus on people’s health and being sustainable therefore also means prioritising environmental protection and a responsibility towards future generations. This is why the Group ensures that it conducts business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the expectations of stakeholders.
Recordati for the community
We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative, an essential part of a healthy business capable of growth but at the same time able to support and develop the community in which it operates and make its employees proud.
Value and diversity of our people
At Recordati, we believe in equal opportunities and we guarantee that everyone can achieve their potential. We see diversity as a value and will not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics. At Recordati, we work hard to create a safe and inclusive work environment, where we all have our rights to physical and psychological integrity respected on a daily basis, as well as our right to freedom of opinion and association. We recognise that we each have a role to play in the success of our business and we implement staff development policies through which everyone’s contribution and achievements can be appropriately rewarded.
Multiple opportunities
Recordati is uniquely structured to bring treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

 

He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.

 

Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.

Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region, Head of Global Endocrinology Franchise

Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.

 

Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

 

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

 

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site